The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) is a huge mover today! About 634,718 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 205.69% since March 9, 2016 and is uptrending. It has outperformed by 198.28% the S&P500.
The move comes after 7 months negative chart setup for the $1.09B company. It was reported on Oct, 12 by Barchart.com. We have $35.79 PT which if reached, will make NASDAQ:AERI worth $76.30 million less.
Analysts await Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report earnings on November, 1. They expect $-0.73 earnings per share, down 5.80% or $0.04 from last year’s $-0.69 per share. After $-0.87 actual earnings per share reported by Aerie Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -16.09% EPS growth.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage
Out of 9 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets on Wednesday, November 4 with “Outperform”. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, September 15. Needham maintained the shares of AERI in a report on Thursday, September 15 with “Buy” rating. The stock has “Buy” rating given by Cantor Fitzgerald on Thursday, September 17. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, September 17 report. The firm has “Buy” rating given on Thursday, October 6 by Stifel Nicolaus. The firm earned “Buy” rating on Thursday, September 15 by Cantor Fitzgerald. The firm has “Buy” rating given on Friday, August 7 by Cantor Fitzgerald. As per Wednesday, September 9, the company rating was initiated by JMP Securities. H.C. Wainwright initiated it with “Buy” rating and $66 target price in Tuesday, September 20 report.
According to Zacks Investment Research, “Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s lead Dual- Action product and Triple-Action products are under developmental stages. Aerie Pharmaceuticals, Inc. is headquartered in Bedminster, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.67 in Q2 2016. Its up 0.28, from 1.39 in 2016Q1. The ratio is positive, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
The Germany-based Dekabank Deutsche Girozentrale has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Dafna Cap Management Limited Liability Co accumulated 160,869 shares or 2.24% of the stock. The Switzerland-based Swiss Fincl Bank has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). The Massachusetts-based Weatherbie Cap Llc has invested 0.9% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Blackrock Inc accumulated 0% or 1,932 shares. Proshare Ltd Com reported 22,695 shares or 0.01% of all its holdings. Fin Consulate has 0.27% invested in the company for 20,000 shares. Gsa Cap Prtnrs Ltd Liability Partnership accumulated 12,437 shares or 0.01% of the stock. Legal And General Group Inc Public Limited Co reported 3,836 shares or 0% of all its holdings. Northern Corporation accumulated 330,379 shares or 0% of the stock. Sectoral Asset Mngmt Inc last reported 88,400 shares in the company. Bailard Incorporated has invested 0.24% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Royal Comml Bank Of Canada has 99,451 shares for 0% of their US portfolio. The New York-based Mufg Americas Holdg has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Bnp Paribas Arbitrage accumulated 937 shares or 0% of the stock.
Insider Transactions: Since July 22, 2016, the stock had 1 buying transaction, and 0 insider sales for $4.38 million net activity. Foresite Capital Management II – LLC also bought $4.38 million worth of Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares.
Another recent and important Aerie Pharmaceuticals Inc (NASDAQ:AERI) news was published by Fool.com which published an article titled: “Why Aerie Pharmaceuticals Is Soaring 54% Today” on September 15, 2016.
AERI Company Profile
Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.